Panacea Index Logo

Command Palette

Search for a command to run...

An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.

Expert opinion on investigational drugs
May 1, 2010
Antoni Camins et al. (7 authors)
Journal ArticleResearch Support, Non-U.S. Gov'tReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate melatonin's potential as a therapeutic agent for neurodegenerative diseases, focusing on its antioxidant and antiapoptotic properties.

Results Summary

The abstract highlights melatonin's natural origin, antioxidant and antiapoptotic effects, and lack of toxicity in humans, though clinical trial data is lacking. It suggests melatonin may be a promising candidate for treating neurodegenerative disorders.

Population

Not specified (general discussion on neurodegenerative diseases).

Effective Dosage

Not specified.

Duration

Not specified.

Interactions

None mentioned.

Extracted Claims (4)
InterventionDirectionEndpointPopulationDosageImpactClaim #
resveratrol
neutral
neurodegenerative diseases
humans
-
attracting considerable attention
#1
melatonin
neutral
neurodegenerative diseases
humans
-
attracting considerable attention
#2
resveratrol
no change
toxicity
humans
-
do not show toxicity
#3
melatonin
no change
toxicity
humans
-
do not show toxicity
#4
Abstract

IMPORTANCE OF THE FIELD: The increase in life expectancy in developed countries has given rise to several emerging social problems. Of particular note is the dramatic rise in the incidence of neurodegenerative diseases. Given this new social scenario, there is a need to identify therapeutic strategies to delay the advance of these pathologies, for which no effective treatment is currently available. AREAS COVERED IN THIS REVIEW: The present review discusses some of the drugs that are now under development with antiapoptotic activity or currently on the market that may have a potential application for the treatment of neurodegenerative diseases. Moreover, we also comment on potential compounds such as resveratrol and melatonin. Despite the lack of information from clinical trials on these two compounds, they are attracting considerable attention because of their natural origin and antioxidant and antiapoptotic action. Furthermore, they do not show toxicity in humans. In addition, we discuss the potential application of several compounds, such as NMDA antagonists, JNK inhibitors and GSK-3 inhibitors, for the treatment of neurodegenerative disorders. WHAT THE READER WILL GAIN: This article will review recent developments in the field of apoptosis inhibitors, which might provide future tools for the treatment of the neurodegenerative diseases. TAKE HOME MESSAGE: The treatment of neurodegenerative diseases is a major challenge in medicine. This is partly because the incidence of these disorders is expected to rise in the coming years. New developments in the field of apoptosis inhibitors may provide future tools for the treatment of the aforementioned neurodegenerative diseases.

Medical Subject Headings (MeSH)
AnimalsApoptosisDrug DesignDrugs, InvestigationalHumansMelatoninMitochondriaNeurodegenerative DiseasesNeuronsNeuroprotective AgentsResveratrolStilbenes
Study Links
Quality Scores
Safety90
Efficacy70/10
Quality60/10
Citation Metrics
Total Citations18
Citations/Year1.2
Relative Citation Ratio0.45
NIH Percentile24.2%
Research Impact Scores
APT Score0.25
Weight Score0.52
Normalized Score0.76
Related Supplements